Tumor-associated neovasculature is a critical therapeutic target; however, despite significant
progress made in the clinical efficacy of anti-vessel drugs, the effect of these agents remains …

Acute myeloid leukemia (AML) is a rapidly progressing disease that is accompanied by a
strong increase in microvessel density in the bone marrow. This observation prompted us to …

The concept of therapeutically enhancing the immune system's responsiveness to tumors is
long standing. Several cytokines have been investigated in clinical trials for their therapeutic …

Purpose: Antibody–drug conjugates and small-molecule-drug conjugates have been
proposed as alternatives to conventional anticancer cytotoxic agents, with the potential to …

The effects of intratumoral (IT) large surface area microparticle paclitaxel (LSAM-PTX) alone
and in combination with systemic administration of the programmed cell death protein …

Abstract Purpose: Interleukin-12 (IL12) is a potent proinflammatory cytokine with antitumor
activity. Its heterodimeric nature makes it compatible with a large variety of different …

Cytokine therapy for cancer has indicated efficacy in certain diseases but is generally
accompanied by severe toxicity. The field of antibody–cytokine fusion proteins …

Interleukin 2 (IL‐2) plays a fundamental role in both immune activation and tolerance and
has revolutionized the field of cancer immunotherapy since its discovery. The ability of IL‐2 …

Since the discovery of cytokines, much effort has been put forth to achieve therapeutic
translation for treatment of various diseases, including cancer and autoimmune diseases …

Systemic high-dose IL2 promotes long-term survival in a subset of metastatic melanoma
patients, but this treatment is accompanied by severe toxicities. The immunocytokine L19 …